# BPC-157 TB-500 Dosage: Animal-Model Research Doses, No Blend Standard

> BPC-157 TB-500 dosage in research context: the animal-model doses studied for each constituent, half-life data, routes, and why no validated blend dose exists.

What was administered to which species, the half-life data, the routes, and the plain fact that no validated dose exists for the blend.

## What doses of BPC-157 and TB-500 have been studied (in animals)?

BPC-157 TB-500 dosage figures in the literature are animal-model research doses for each constituent — not human guidance, and not a validated dose for the blend. There is no peer-reviewed combination dose-finding study at all.

The BPC-157 component, in rodents, was commonly expressed per body weight: the transected-Achilles-tendon work used roughly 10 microg/kg and 10 ng/kg [1], and gastric-ulcer cytoprotection has been studied in the 400-800 ng/kg range. The TB-500/Thymosin Beta-4 component spans a far wider range — for example, 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study, where the modeled optimum was around 3.75 mg/kg and the top 18 mg/kg dose gave no benefit, and 150 microg twice weekly for six months in an mdx muscular-dystrophy model. The non-monotonic stroke result is worth sitting with: higher was not better, which undercuts "loading" rationales.

Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend: intravenous Thymosin Beta-4 was well tolerated to high doses in early-phase safety work. Community "loading then maintenance" blend protocols and fixed-ratio vials have no controlled-trial basis [8] and are not presented here as validated dosing.

## How is a BPC-157 / TB-500 blend reconstituted?

### How is a BPC-157 / TB-500 blend reconstituted?

Both peptides are supplied as lyophilized (freeze-dried) powders, reconstituted in bacteriostatic or sterile water and refrigerated for research handling. A common practice is to reconstitute the two separately or in a shared vial. Critically, product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated "Wolverine" material are not guaranteed, which compounds the existing TB-500 identity caveat (fragment versus full-length Thymosin Beta-4) [7].

### How the Wolverine blend is handled in research settings

In research settings the constituents are reconstituted and administered parenterally — subcutaneous and intramuscular are the predominant research-community routes, while intraperitoneal dominates the underlying rodent efficacy studies [1]. This describes handling in the literature; it is not human-use guidance, and no validated administration protocol exists for the blend.

### How often is BPC-157 and TB-500 administered in research?

There is no validated dosing schedule for the blend. Community "loading then maintenance" protocols have no controlled-trial basis [8], and the non-monotonic Thymosin Beta-4 stroke data (18 mg/kg gave no benefit) argues directly against assuming more-is-better frequency.

## Oral, injectable, half-life, and the 'wolverine injection' question

### Oral versus injectable BPC-157 / TB-500 in the literature

BPC-157 is studied as a "stable gastric" peptide, which is why oral BPC-157 appears in the literature at all; TB-500/Thymosin Beta-4 evidence is overwhelmingly parenteral [4][6]. Oral blend products are marketed but lack validated pharmacokinetics, so "bpc 157 tb 500 oral" has no established absorption profile for the combination.

### How is the 'wolverine injection' handled in research?

The "wolverine injection" framing refers to the parenteral handling of the two constituents in research — predominantly subcutaneous or intramuscular in the research community, intraperitoneal in the rodent source studies [1]. No controlled human injection protocol exists for the blend, and nothing here is administration guidance.

### What is the half-life of BPC-157 and TB-500?

BPC-157's elimination half-life was reported as under 30 minutes in an animal pharmacokinetic study. No validated half-life is established for the TB-500 heptapeptide, and none for the blend; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics, but that is the full-length protein, not the fragment.

## Why these numbers do not transfer to the blend

Three things make the constituent dose figures impossible to roll up into a blend dose. First, the units don't even match: BPC-157's rodent doses are typically microgram- and nanogram-per-kilogram (about 10 microg/kg in the tendon work) [1], while the TB-500/Thymosin Beta-4 figures run in milligrams per kilogram (2-18 mg/kg in the embolic-stroke study). They live on different scales, so a fixed-mass vial pairing them tells you nothing about a matched effective ratio.

Second, the TB-500 identity gap distorts any dose read. The wide-range animal figures attributed to "TB-500" were generated with full-length Thymosin Beta-4, not the Ac-LKKTETQ heptapeptide that is sold [7], so even the per-constituent numbers describe a different molecule than the one in the vial.

Third, the dose-response is non-monotonic where it has been mapped: the rat stroke study modeled an optimum near 3.75 mg/kg with the top 18 mg/kg dose giving no benefit. "More" was not better. Taken together, there is no defensible way to extrapolate a human blend dose from this record, and none is offered here [8].

---

A versus-screen reading of the BPC-157 TB-500 blend — each peptide racked against its own studies, the combination row left at NO MATCH ON RECORD, and the FDA and WADA status called before the bell, with no clinic in the corner and nothing here for sale.